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ABSTRACT
Bacteria harbouring the novel qnrA plasmid-mediated mechanism of quinolone resistance have been
described in different countries, but the frequency of their occurrence has not been investigated. In total,
1468 clinical isolates of Enterobacteriaceae with quinolone resistance or extended-spectrum b-lactamase
(ESBL) phenotypes were collected from eight teaching hospitals in France during 2002–2005 and
screened for qnrA. Overall, 28 isolates (22 Enterobacter cloacae, three Klebsiella pneumoniae, one Citrobacter
freundii, one Klebsiella oxytoca and one Proteus mirabilis) were positive for qnrA, representing 1.9% of all
isolates, 3.3% of ESBL-producing isolates (22% of the E. cloacae isolates) and 0% of non-ESBL-producing
isolates. The prevalence of qnrA among consecutive ESBL-producing isolates in 2004 from the eight
hospitals was 2.8% (18 ⁄ 639). Of the qnrA-positive isolates, 100% were intermediately-resistant or
resistant to nalidixic acid, and 75% to ciproﬂoxacin. Twenty-one of the 22 qnrA-positive E. cloacae
isolates were obtained from two hospitals in the Paris area, and molecular typing and plasmid content
analysis showed clonal relationships for ﬁve, three and two isolates, respectively. The qnrA genetic
environment was similar to that of the In36 integron. The remaining two isolates had qnrA variants (30
and 29 nucleotide differences, respectively, compared with the original sequence) and an unknown
genetic environment. The ESBL gene associated with qnrA was blaSHV-12 in most of the isolates, but
blaPER-1 and blaSHV-2a were found in two isolates. In France, it appears that qnrA-positive isolates are
predominantly E. cloacae isolates producing SHV-12, and may be associated with the dissemination of an
In36-like integron.
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INTRODUCTION
Plasmid-mediated resistance to quinolones was
ﬁrst described in 1998 [1], following 20 years
during which quinolone resistance was restric-
ted to chromosomally-encoded mechanisms. The
plasmid-mediated quinolone resistance gene,
qnrA, was shown to be transferable by conjuga-
tion from the original Klebsiella pneumoniae isolate
to Escherichia coli [1]. The mechanism of resistance
encoded by qnrA was novel, involving protection
of DNA gyrase from quinolone inhibition by the
Qnr protein [2].
Classically, chromosomally-encoded mecha-
nisms of quinolone resistance mostly involve
target site alterations following amino-acid
substitutions in the subunits of DNA gyrase
(mutations in the gyrA and gyrB genes) or topo-
isomerase IV (mutations in the parC and parE
genes) [3]. Decreased quinolone uptake, associated
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with diminished permeability in Gram-negative
bacilli or mycobacteria, and increased efﬂux in
several other bacterial species, have also been
described, and result from mutations in chromo-
somal regulatory genes [4]. None of these mecha-
nisms, studied extensively since 1977, is
transferable between bacterial cells.
New plasmid-mediated qnr genes, qnrS [5] and
qnrB [6], have recently been described. These new
genes are 40–60% homologous to the gene dis-
covered by Martinez-Martinez et al. [1], which has
now been named qnrA. Chromosomal homo-
logues of qnr have been discovered in the ge-
nomes of various environmental bacteria, such as
Photobacterium profundum [5], Vibrionaceae and
Shewanella algae [7]. The primary structure of
QnrA (218 amino-acids) indicates that it belongs
to the family of pentapeptide repeat proteins [8].
The proteins belonging to this family with the
closest similarity (20% at most) to QnrA are the
McbG protein that protects DNA gyrase from
microcin B17 toxin [9], and MfpA isolated from
Mycobacterium smegmatis, both of which also
confer low-level quinolone resistance [10]. The
transferable qnrA gene is usually carried by large
conjugative plasmids (50–180 kb) that also carry
plasmid-mediated AmpC-type b-lactamase or
extended-spectrum b-lactamase (ESBL) genes
[2,11,12]. The qnrA gene has also been shown to
form part of class 1 integrons, together with other
antibiotic resistance cassettes [2,11–13].
Since 2003, qnrA-positive isolates have been
reported from several geographical regions in
the USA [12,14–16], Asia [11,17–19] and Europe
[13,17,20,21] in various species, but mostly in
Esch. coli [11,13,18], K. pneumoniae [12,14,15] and
Enterobacter cloacae [16,17,21]. However, to date,
the precise burden of quinolone resistance
caused by this new mechanism has not been
quantiﬁed.
The objective of the present study was to
investigate clinical isolates of Enterobacteriaceae,
collected through a network of French teaching
hospitals, for the presence of the QnrA-based
resistance mechanism. Quinolone-resistant and
ESBL-producing isolates from the period 2002–
2005 were screened by PCR for the qnrA gene.
Clonal relationships among the qnrA-positive
isolates were assessed by molecular typing and
analysis of the plasmid content. The qnrA-positive
isolates were also characterised by sequencing the
qnr-containing region and by determining the
antibiotic resistance patterns and ESBL genes
carried on the same resistance plasmid.
MATERIALS AND METHODS
Bacterial isolates
Non-duplicate isolates of Enterobacteriaceae were collected,
according to published recommendations for resistance sur-
veillance [22], from patients hospitalised between 2002 and
2005 in eight teaching hospitals located throughout France
(Hoˆpital Pellegrin, Bordeaux; Hoˆpital Gabriel Montpied, Cler-
mont-Ferrand; Hoˆpital Henri Mondor, Cre´teil; Hoˆpital Charles
Foix, Ivry sur Seine; Hoˆpital Dupuytren, Limoges; Hoˆpital
Europe´en Georges Pompidou, Paris; Hoˆpital Pitie´-Salpe´trie`re,
Paris; Hoˆpital d’Instruction des Arme´es Be´gin, Saint-Mande´).
For inclusion in the study, isolates had to display reduced
susceptibility (intermediately-resistant or resistant) to nalidixic
acid and ciproﬂoxacin [23] (http://www.sfm.asso.fr), or sus-
pected production of an ESBL [24–26] or a plasmid-mediated
AmpC-type b-lactamase [27]. Antibiotic susceptibility patterns
were determined by the disk-diffusion method (Biorad,
Marnes La Coquette, France) on Mueller–Hinton agar, and
MICs were determined by the Etest method (AES, Combourg,
France). Negative controls for PCR were quinolone- and b-
lactam-susceptible isolates (12 Esch. coli, eight K. pneumoniae,
ten Ent. cloacae), and the positive control was K. pneumoniae
strain UAB1 [1] (kindly supplied by D. C. Hooper).
Study periods
There were three successive study periods. During the ﬁrst
period, 361 consecutive isolates from 2002 with reduced
susceptibility to quinolones were tested retrospectively. Dur-
ing the second period, isolates from November 2003 to January
2004 were tested, including (i) isolates of Esch. coli or K. pneu-
moniaewith reduced susceptibility to quinolones (n = 285), and
(ii) isolates suspected to produce an ESBL (n = 91) or a
plasmid-mediated AmpC-type b-lactamase (n = 3), regardless
of species or their susceptibility to quinolones. Since only
ESBL-producing isolates were qnrA-positive during the ﬁrst
two periods, the third period determined the proportion of
qnrA-positive isolates among ESBL-producing isolates with an
epidemiological signiﬁcance. Therefore, all consecutive ESBL-
producing isolates (n = 639) during 2004 from the eight
hospitals were tested for qnrA. The third period was prolonged
to the ﬁrst trimester of 2005 in two hospitals, and 89 additional
ESBL-producing isolates were tested.
PCR detection and sequencing of the qnrA gene
Total DNA was extracted by a heat-shock method. In brief, one
loopful of freshly-grown colonies was emulsiﬁed in 150 lL of
sterile water, heated for 5 min at 95C, and then cooled
immediately on ice. Following centrifugation for 2 min at
13 000 g, the supernatant was transferred to a 96-well micro-
plate. A ﬁrst PCR (PCR1) was performed on all the isolates
using primers (Table 1) amplifying an intragenic qnrA 543-bp
fragment (GenBank accession number AY070235). All the
isolates positive by PCR1 were tested with two other pairs of
primers (Table 1), generating an intragenic 627-bp fragment
(PCR2) and a 661-bp fragment (PCR3) encompassing the
whole qnrA gene. Each ampliﬁcation mixture contained 5 lL of
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total DNA extract, 0.5 lM each primer (Proligo, Paris, France),
0.25 mM dNTPs (Amersham Biosciences, Orsay, France) and
1.25 U of Taq polymerase (Qbiogene, Illkirch, France). PCRs
comprised 30 cycles of 94C for 30 s, 57C for PCR1, or 50C for
PCR2 and PCR3, for 30 s, and 72C for 30 s. PCR was
performed in 96-well microplates with a positive control
(K. pneumoniae UAB1) and two negative controls (water
and Esch. coli KL16). PCR products were visualised follow-
ing electrophoresis in agarose 2% w ⁄v gels in Tris-borate
buffer.
For all isolates for which the three PCRs were positive, the
661-bp fragment from PCR3 was puriﬁed with the Montage
PCR puriﬁcation kit (Millipore, Saint Quentin-en-Yvelines,
France), following the manufacturer’s recommendations.
Sequencing was then performed using the Big Dye Terminator
kit v.3.1 (Applied Biosystems, Courtaboeuf, France), 300 ng of
puriﬁed DNA, 0.6 pmol primers ⁄ lL, and an ABI PRISM 3100
automated sequencer (Applied Biosystems). Sequences ob-
tained were analysed with SeqScape software (Applied Bio-
systems) and compared with the BioEdit Sequence Alignment
program (Isis Pharmaceuticals, Carlsbad, CA, USA).
Analysis of qnrA-containing plasmids
Plasmid DNA was extracted using a High Speed Plasmid Midi
kit (Qiagen, Courtaboeuf, France) and compared following
restriction with EcoRI and BamHI and electrophoresis on
agarose 0.7% w ⁄v gels. Sequences upstream and downstream
of the qnr gene were determined by PCR sequencing using a
sense primer (Table 1) in the middle of orf513 [28] and an
antisense primer (Table 1) at the beginning of qacED1, which
are two sequences often described in sul1-type integrons.
Genes encoding ESBLs of the TEM and the SHV types [25]
were identiﬁed by PCR using the primers listed in Table 1.
Conjugation experiments were performed in brain–heart
infusion broth with a sodium azide-resistant mutant of
Esch. coli BM13 J53 (rifampicin-resistant) [29] as the recipient.
Donor and recipient cells in the logarithmic phase of growth
were mixed (2 mL each) and incubated for 40 min without
shaking. Transconjugant clones were selected on Mueller–
Hinton agar plates containing rifampicin 250 mg ⁄L, sodium
azide 100 mg ⁄L, and either ampicillin 100 mg ⁄L, amikacin
10 mg ⁄L or sulphamethoxazole 300 mg ⁄L.
Molecular typing
Total DNA from each qnrA-positive strain was analysed by
enterobacterial repetitive intergenic consensus (ERIC) se-
quence PCR with the ERIC2 primer, and random ampliﬁed
polymorphic DNA using primers 1254 (5¢-CCGCAGCCAA)
and 1281 (5¢-AACGCGCAAC), as described previously [20–
32].
RESULTS
Isolates positive for qnrA
Table 2 summarises the bacterial species included
in the study, the numbers positive for ESBL
production, and the percentage of isolates that
were qnrA-positive. Table 3 summarises the
quinolone susceptibility patterns of the isolates
included in the study. Overall, the three PCRs for
qnrA detection were positive for 28 (1.9%) of the
1468 isolates; the positive isolates comprised 28
(3.3%) of 841 ESBL-producing isolates, and none
of the 627 non-ESBL-producing isolates. Only
three isolates with a plasmid-mediated AmpC-
type b-lactamase phenotype were collected (two
K. pneumoniae, one Proteus mirabilis), and none of
these was qnrA-positive.
The 28 qnrA-positive isolates comprised 22
Ent. cloacae, three K. pneumoniae, one Citrobacter
freundii, one Klebsiella oxytoca and one Proteus
mirabilis. Although Esch. coli represented half of
the isolates tested, none was qnrA-positive
(Table 2). The 28 qnrA-positive isolates were
obtained from six of the eight teaching hospitals,
with a majority (n = 24) of isolates from only two
hospitals located in the Paris area. A single qnrA-
Table 1. Primers used for PCR experiments in this study
Gene Sense primer Antisense primer Reference
qnrA PCR1 5¢-GATAAAGTTTTTCAGCAAGAGG 5¢-ATCCAGATCGGCAAAGGTTA [14]
qnrA PCR2 5¢-TCAGCAAGAGGATTTCTCA 5¢-GGCAGCACTATTACTCCCA [11]
qnrA PCR3 5¢-GGGTATGGATATTATTGATAAAG 5¢-CTAATCCGGCAGCACTATTA [11]
orf513 5¢-TCGCATCGCTCGCTGCATG 5¢-GCGAAAACGGCTGTCACTC [28], this study
qacED1 5¢-GTCAAGATCTGTGCCCTGGCA 5¢-CAAGCTTTTGCCCATGAAGC [29], this study
blaTEM 5¢-GAGTATTCAACATTTCCGTGTC 5¢-TAATCAGTGAGGCACCTATCTC This study
blaSHV 5¢-GCGTTGCCAGTGCTCGATCAGCGC 5¢-ATGCGTTATATTCGCCTGTGTATT This study
Table 2. Distribution of the 1468 isolates tested according
to bacterial species, production of extended-spectrum
b-lactamase (ESBL) and the presence of qnrA
Bacterial species
Total isolates
(n = 1468)
n
ESBL isolates
(n = 841)
n
qnrA-positive isolates
n
% of total
isolates
% of ESBL
isolates
Escherichia coli 857 385 0 0 0
Klebsiella pneumoniae 269 192 3 1.1 1.6
Enterobacter cloacae 135 100 22 16.3 22
Enterobacter aerogenes 63 61 0 0 0
Citrobacter freundii 40 17 1 2.5 5.9
Klebsiella oxytoca 28 27 1 3.6 3.7
Citrobacter koseri 24 24 0 0 0
Proteus mirabilis 19 16 1 5.3 6.2
Serratia marcescens 17 6 0 0 0
Othersa 14 11 0 0 0
aMorganella morganii (n = 5), Proteus vulgaris (n = 5), Proteus stuartii (n = 1), Proteus
rettgeri (n = 1), Proteus penneri (n = 1), Serratia liquefaciens (n = 1).
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positive isolate was obtained from each of four
other hospitals, but no qnrA-positive isolates were
obtained from the two remaining hospitals, both
located in the central region of France (Limoges
and Clermont-Ferrand).
The proportion of qnrA-positive isolates
among ESBL-positive isolates during the third
study period, i.e., 2004, ranged from 0% (three
hospitals) to 10.5%, according to the hospital,
with four hospitals having proportions between
0.8% and 1.9%. In these hospitals, the mean
annual incidence density of ESBL-producing
isolates during 2004 was 0.2 ⁄ 1000 hospitalisa-
tion-days, giving an incidence density of
c. 0.02 ⁄ 1000 hospitalisation-days for qnrA-posit-
ive isolates in the participating hospitals. In the
two hospitals that provided the majority of the
qnrA-positive isolates, the proportion of qnrA-
positive isolates among ESBL-producing isolates
did not increase signiﬁcantly over time, ranging
from 1 ⁄ 19 (5.2%) in 2002, to 7 ⁄ 94 (7.4%) in 2003,
and 15 ⁄ 282 (5.3%) in 2004 (p 0.62, chi-square test
for trend).
None of the qnrA-positive isolates was suscept-
ible to nalidixic acid, contrasting with 11.5% of
ESBL-producing isolates (Table 3). However, 25%
(7 ⁄ 28) of the qnrA-positive isolates were suscept-
ible to ciproﬂoxacin. There were more isolates
resistant to ciproﬂoxacin among qnrA-negative
ESBL-producing isolates (77.9%) than among
qnrA-positive ESBL-producing isolates (57.1%)
(p <0.01; chi-square test). All qnrA-positive iso-
lates displayed a multidrug resistance pattern in
addition to the ESBL and quinolone resistance
phenotypes (Table 4).
Molecular typing of the 22 qnrA-positive
Ent. cloacae isolates by ERIC-PCR and rapid
ampliﬁed polymorphic DNA analysis yielded
concordant results, and grouped 11 of the 22
isolates into three clusters (Table 4). Cluster 1
comprised six of the 16 Ent. cloacae isolates from
Pitie´-Salpeˆtrie`re Hospital. Cluster 2 grouped two
isolates from different periods at Henri Mondor
Hospital (Hm46, Hm190) with one isolate from
Pitie´-Salpeˆtrie`re Hospital (Ps88); however, all
three patients had been hospitalised previously
during the same period in the same long-term
care hospital. Cluster 3 included one isolate from
Pitie´-Salpeˆtrie`re Hospital (Ps75) and one isolate
from Henri Mondor Hospital (Hm477). Chart
review revealed that the patient harbouring
Hm477 had been hospitalised at Pitie´-Salpeˆtrie`re
Hospital 7 months previously. The remaining 11
Ent. cloacae isolates did not form clusters on the
basis of DNA ﬁngerprinting.
Molecular characterisation of the qnrA gene
For 26 of 28 isolates, the qnrA sequences were
identical to the gene described in the original
K. pneumoniae UAB1 isolate, with a silent muta-
tion (nucleotide 537, CTA ﬁ CTG) in the leu-
cine codon at position 179. The Prot. mirabilis
isolate and K. pneumoniae He96 harboured new
qnrA alleles, which differed from the original
gene by 30 and 29 nucleotides (GenBank acces-
sion numbers DQ151889 and DQ435306), lead-
ing to ﬁve and three amino-acid differences,
respectively.
Plasmids extracted from the qnrA-positive iso-
lates ranged in size from 20 to 100 kb. Plasmid
restriction proﬁles within cluster 1 were similar,
except for the plasmid from Ps45, which showed
additional EcoRI and BamH1 restriction fragments
(data not shown). The ESBL genes detected in
plasmid extracts were SHV-12 (23 isolates),
SHV-2a (one K. pneumoniae), and PER-1 (one
Prot. mirabilis) (Table 4). For K. pneumoniae He96,
Ent. cloacae Ps25 and Ent. cloacae Cf84, no ESBL
genes belonging to the TEM or the SHV types
were detected, although the presence of other
possible ESBL types remains to be investigated.
For 25 isolates (22 Ent. cloacae, two K. pneumoniae
and one K. oxytoca), sequences upstream and
Table 3. Quinolone resistance pat-
ternsa of the clinical isolates tested
for qnrA
Isolates
Cip-S + Nal-S
n (%)
Cip-S + Nal-I
n (%)
Cip-S + Nal-R
n (%)
CipI + NalR
n (%)
Cip-R + Nal-R
n (%)
Total enterobacterial isolates
n = 1468 97 (6.6) 49 (3.3) 261 (17.8) 69 (4.7) 992 (67.6)
ESBL-producing isolates
n = 841 97 (11.5) 15 (1.8) 53 (6.3) 31 (3.7) 645 (76.7)
qnrA-positive isolates
n = 28 0 (0) 3 (10.7) 4 (14.3) 5 (17.9) 16 (57.1)
aMIC breakpoints and interpretation: S £ 1 mg ⁄L, R > 2 mg ⁄L, I > 1- £ 2 mg ⁄L for ciproﬂoxacin; S £ 8 mg ⁄L,
R > 16 mg ⁄L, I 8- £ 16 mg ⁄L for nalidixic acid.
CIP, ciproﬂoxacin; NAL, nalidixic acid.
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downstream of qnrA were identical to those of
plasmids pHSH1 and pHSH2 (GenBank accession
numbers AY259085 and AY259086) described
previously [11], with qnrA downstream of orf513
(encoding a putative recombinase) and upstream
of ampR (the repressor gene for AmpC-type
b-lactamase) and qacED1 (a gene with a deletion
that would otherwise encode resistance to qua-
ternary ammonium compounds). For the C. fre-
undii isolate, the sequence upstream of qnrA was
identical to pHSH1, but the sequence downstream
was cmlA, a chloramphenicol resistance gene. To
date, all attempts to sequence upstream or down-
stream of qnrA in the Prot. mirabilis isolate and
K. pneumoniae He96 have been unsuccessful.
Transfer of qnrA from Ent. cloacae Hm477 to
Esch. coli BM13 conﬁrmed that qnrA conferred
quinolone resistance, with a two- to 24-fold
increase in quinolone MICs (Table 5). However,
MICs for the transconjugant were below the
recommended ciproﬂoxacin susceptibility break-
points of 1 mg ⁄L (CLSI; http://www.clsi.org)
and 0.5 mg ⁄L (EUCAST, http://www.eucast.
org). Co-transfer of resistance to b-lactams
occurred, including extended-spectrum agents,
and some of the other resistances observed in
the parental strain (Table 5).
Table 4. Characteristics of the 28 qnrA-positive clinical isolates, showing genetic clustering, quinolone MICs, antibiotic
resistance pattern, and extended-spectrum b-lactamases (ESBLs) encoded
Cluster Isolate
MIC (mg ⁄L) Antibiotic resistance pattern
ESBL encodedNal Cip Tzp Ctx Caz Gen Amk Tet Chl Sxt
1 Enterobacter cloacae Ps51 >256 16 S I R R I R R R SHV-12
1 Ent. cloacae Ps45 >256 64 S I R R R R R R SHV-12
1 Ent. cloacae Ps39 >256 32 S I R R I R R R SHV-12
1 Ent. cloacae Ps86 >256 128 S I R R I R R R SHV-12
1 Ent. cloacae Ps87 >256 64 S I R R I R R R SHV-12
1 Ent. cloacae Ps84 >256 32 S I R R R R R R SHV-12
2 Ent. cloacae Hm46 >256 1 S I R S I S S R SHV-12
2 Ent. cloacae Hm190 >256 0.5 S I R R I S R R SHV-12
2 Ent. cloacae Ps88 >256 2 R R R R I S S R SHV-12
3 Ent. cloacae Hm477 >256 16 S I R S R R S R SHV-12
3 Ent. cloacae Ps75 >256 16 S I R S R R R R SHV-12
No Ent. cloacae Ps20 >256 4 R R R R I R R R SHV-12
No Ent. cloacae Ps31 16 1 R R R R I R R R SHV-12
No Ent. cloacae Ps139 >256 8 I R R R R R R R SHV-12
No Ent. cloacae Ps127 16 0.5 S I R R I R R R SHV-12
No Ent. cloacae Ps79 >256 32 R R R R S R S R SHV-12
No Ent. cloacae Ps93 >256 2 S I R R S R S R SHV-12
No Ent. cloacae Ps23 >256 2 I I R S S R R S SHV-12
No Ent. cloacae Ps25 32 4 R R R I S R R S Unknowna
No Ent. cloacae Cf84 >256 2 R R R S R R S R Unknowna
No Ent. cloacae Hm179 64 1 S I R R I S R R SHV-12
No Ent. cloacae Hm0553 >256 8 I R R R S R S R SHV-12
– Klebsiella pneumoniae Ps116 >256 >32 I I R R R R R R SHV-2a
– K. pneumoniae He96 128 8 I R R R I R S R Unknowna
– K. pneumoniae Bg0502 >256 >32 I R R S R R R R SHV-12
– Klebsiella oxytoca Bdx70 16 0.25 S I R I I R S S SHV-12
– Proteus mirabilis Ps16 >256 1 S I R R R R R R PER-1
– Citrobacter freundii Ps103 >256 12 I R R R I R R R SHV-12
Nal, nalidixic acid; Cip, ciproﬂoxacin; Tzp, piperacillin–tazobactam; Ctx, cefotaxime; Caz, ceftazidime; Gen, gentamicin; Amk, amikacin; Tet, tetracycline; Chl,
chloramphenicol; Sxt, co-trimoxazole; –, not determined.
Ps from Pitie´-Salpeˆtrie`re Hospital; Hm from Henri Mondor Hospital; Cf from Charles Foix Hospital; He from HEGP Hospital; Bg from Begin Hospital; Bdx from Bordeaux-
Pellegrin Hospital.
anot belonging to the TEM or SHV types.
Table 5. Antibiotic susceptibility patterns and MICs for
the Escherichia coli transconjugants obtained in conjugation
experiments with clinical isolate Enterobacter cloacae
HM477 as the donor and Esch. coli BM13 as the recipient
Antibiotic
MICs (mg ⁄L)
Transconjugant
(fold increase)
Ent. cloacae
Hm477
Esch. coli
BM13
Nalidixic acid >128 4 8 (·2)
Oﬂoxacin >16 0.05 0.75 (·15)
Levoﬂoxacin >16 0.02 0.25 (·10)
Ciproﬂoxacin >32 0.004 0.094 (·24)
Moxiﬂoxacin >16 0.03 0.38 (·12)
Piperacillin 256 0.75 32 (·40)
Cefotaxime 8 0.03 0.75 (·25)
Ceftriaxone 6 0.01 0.25 (·25)
Ceftazidime 64 0.06 3 (·50)
Cefepime 0.5 0.02 0.125 (·6)
Imipenem 0.25 0.19 0.125 (·1)
Gentamicin 1.5 0.06 0.25 (·4)
Netilmicin 128 0.12 12 (·100)
Amikacin 48 0.4 12 (·40)
Tetracycline R S S
Trimethoprim R S R
Sulphonamides R S S
Chloramphenicol R S S
S, susceptible; R, resistant.
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DISCUSSION
The objective of the present study was to assess
the importance of the new plasmid-mediated
Qnr-based mechanism of quinolone resistance
among Enterobacteriaceae in France. During
2002–2005, qnrA was found exclusively in ESBL-
producing isolates, and mainly in Ent. cloacae
isolates harbouring the gene encoding SHV-12.
Since the description of the original K. pneumoniae
isolate in Alabama, USA, in 1994 [1], c. 80
qnrA-positive isolates belonging to various spe-
cies have been described worldwide [11–21]. Most
of these isolates pre-date 2003 and have been
obtained from strain collections [12,14–16] or
single hospitals [11,13,18–21], thereby preventing
assessment of the magnitude of the phenomenon.
The present survey included isolates obtained
between 2002 and 2005 from eight hospitals
located throughout France, with qnrA-positive
isolates representing 1.9% of all enterobacteria
included in the present study, and all of the
qnrA-positive isolates being ESBL producers. The
results from 2004 indicate a prevalence of 2.8%
for qnrA-positive isolates among ESBL producers,
giving an estimated number of 400 qnrA-positive
isolates annually in French hospitals, since the
number of ESBL-producing isolates is c. 15 000
annually, with an incidence density of 0.2 ⁄ 1000
hospitalisation-days (RAISIN nationwide survey;
http://www.invs.sante.fr.).
As two hospitals located in the Paris region
accounted for 24 ⁄ 28 qnrA-positive isolates and
21 ⁄ 22 qnrA-positive Ent. cloacae isolates, possible
clonality was investigated, as described previ-
ously for ESBL-producing isolates [26]. Molecular
typing showed that 10 ⁄ 28 isolates belonged to
three genotypic clusters.
In the present study, all qnrA-positive isolates
were ESBL producers. To date, qnrA has been
associated with class 1 integrons, where multiple
resistance gene cassettes are integrated [2,11–
13,33]. However, apart from uncommon ESBLs,
e.g., VEB, GES and CTX-M-9 [17,25,26], ESBL
genes are usually not inserted as cassettes in class
1 integrons, and class 1 integrons occur at a
similar frequency (c. 40%) in ESBL-positive and
ESBL-negative isolates of Esch. coli [34]. There-
fore, the observed association between qnrA and
ESBL genes requires further investigation. In the
present study, the association was mostly with
SHV-12, ﬁrst described in Switzerland [35], in
contrast to the ﬁrst studies of qnrA in the USA, in
which the plasmid-mediated AmpC-type b-lacta-
mase FOX-5 and the SHV-7 ESBL were found
[12,14,15], and to the two isolates reported previ-
ously from France and one isolate from Turkey,
which contained the VEB-1 gene [13,17,36]. An
epidemiological study of 157 ESBL-producing
isolates of Esch. coli from France during 2001
revealed that only 11 produced SHV-12, and none
of the SHV-12 producers harboured qnrA [37].
This suggests that the association of qnrA with
SHV-12 is recent or may occur preferentially in
Ent. cloacae. A similar association was found in
the K. pneumoniae and C. freundii isolates in the
present study, and has also been reported previ-
ously in the UK [21].
The sequences of the qnrA genetic environ-
ment (orf513–qnr–ampR–qacED1–sul1), as well as
the qnrA gene itself (qnrA with a silent mutation
at nucleotide 537), were identical in 25 ⁄ 28 iso-
lates. These sequences were the same as those
described in Esch. coli strains from Shanghai [11],
but differ from observations in the USA and
Europe that revealed a different genetic environ-
ment and integron structures [12–14]. Since the
qnrA genetic environment appears to be similar
to the pSAL-1 plasmid conﬁguration [38], in
which ampC and ampR are co-inserted down-
stream of orf513, an insertion of qnrA between
orf513 and ampR, associated with a deletion of
ampC, can be hypothesised. In isolates from
France, it seems that dissemination of an In36-
or In37-like integron may be occurring, as
opposed to new qnrA integration events in
strains that already harbour sul1-type integrons.
The In36- or In37-like integrons and plasmids
carrying SHV-12 seem to have combined very
successfully in nosocomial strains of Ent. cloacae.
Interestingly, the new qnrA variants described in
the present study have a totally different genetic
environment, which indicates that qnrA variants
and qnr alleles are each related to a speciﬁc
genetic environment.
It has been hypothesised that qnr emerged
among clinical strains because of the selective
pressure of quinolones [1,6,11]. However, the low
level of resistance conferred by qnrA (this study)
[39,40] does not seem to be sufﬁcient to enable
clinical selection, and most of the qnrA-positive
isolates to date, including 15 ⁄ 28 isolates in the
present study, were highly resistant to cipro-
ﬂoxacin (MIC >4 mg ⁄L), probably because of
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additional quinolone resistance mechanisms. Two
possible scenarios can be proposed: (i) qnrA was
acquired under quinolone selective pressure
because it facilitates the acquisition of successive
steps of quinolone resistance, as observed in vitro
[14,40]; or (ii) qnrA was acquired by strains
containing sul1-type integrons because of illegit-
imate recombination events, regardless of the
quinolone selective pressure and the quinolone
resistance level of the recipient strain. Since (a)
most ESBL producers do not harbour qnrA but
harbour integrons [34], (b) ESBL producers are
more resistant to ciproﬂoxacin than qnrA-positive
isolates (Table 3), and (c) class 1 integrons are
more prevalent among ciproﬂoxacin-resistant iso-
lates than among their susceptible counterparts
[41], the second scenario, in which qnrA integra-
tion is more of a genetic accident than a selected
characteristic for the bacterial isolate, seems to be
more likely.
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